| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 06/23/2005 | US20050137414 New aminopropylphosphinic acids |
| 06/23/2005 | US20050137232 Histone deacetylase inhibitors |
| 06/23/2005 | US20050137223 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| 06/23/2005 | US20050137220 Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
| 06/23/2005 | US20050137189 For therapy of Gram-positive bacterial infection |
| 06/23/2005 | US20050137185 Combinations of drugs for the treatment of neoplasms |
| 06/23/2005 | US20050137169 Vinca derivatives |
| 06/23/2005 | US20050137154 administering human alpha interferon, double-stranded ribonucleic acid (dsRNA) and/or mixtures for the treatment of respiratory system disorders |
| 06/23/2005 | US20050137150 Forms of 5-azacytidine |
| 06/23/2005 | US20050136429 SIRT1 modulation of adipogenesis and adipose function |
| 06/23/2005 | US20050136104 Chewable soft capsules containing ungelatinized starch |
| 06/23/2005 | US20050136070 Isolation and characterization of the csa operon (ETEC-CS4 Pili) and methods of using same |
| 06/23/2005 | US20050136062 Treatment of IgA1 deposition diseases |
| 06/23/2005 | US20050136054 Humanised antibodies |
| 06/23/2005 | US20050136042 Methods and compositions for tissue repair |
| 06/23/2005 | US20050136037 Bacteriophage for lysis of Methylobacterium and compositions and uses thereof |
| 06/23/2005 | US20050136036 Methods and compositions for the treatment of neurological disease |
| 06/23/2005 | CA2552279A1 Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors |
| 06/23/2005 | CA2549736A1 Cationic substituted benzofurans as antimicrobial agents |
| 06/23/2005 | CA2549413A1 Glycopegylated factor ix |
| 06/23/2005 | CA2549409A1 Glycopegylated granulocyte colony stimulating factor |
| 06/23/2005 | CA2549273A1 Novel m3 muscarinic acetylcholine receptor antagonists |
| 06/23/2005 | CA2549272A1 Novel m3 muscarinic acetylcholine receptor antagonists |
| 06/23/2005 | CA2549240A1 Branched sulfates with improved odor properties and their use in personal care compositions |
| 06/23/2005 | CA2549104A1 Influenza immunogen and vaccine |
| 06/23/2005 | CA2548892A1 Compositions for treatment of ear disorders and methods of use thereof |
| 06/23/2005 | CA2548822A1 Mucoadhesive drug delivery devices and methods of making and using thereof |
| 06/23/2005 | CA2548491A1 Synergistic anti-cancer compositions |
| 06/23/2005 | CA2548487A1 Methods and compositions for slowing aging |
| 06/23/2005 | CA2548180A1 Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| 06/23/2005 | CA2548149A1 Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
| 06/23/2005 | CA2548144A1 Dosing methods for .beta.-d-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy |
| 06/23/2005 | CA2548140A1 Oligosaccharide compositions and use thereof in the treatment of infection |
| 06/23/2005 | CA2547621A1 Transdermal system for sustained delivery of polypeptides |
| 06/23/2005 | CA2547570A1 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for induction of fetal hemoglobin in individuals having anemia |
| 06/23/2005 | CA2547569A1 Recombinant factor viii having increased specific activity |
| 06/23/2005 | CA2546053A1 Amelioration of cataracts, macular degeneration and other ophthalmic diseases |
| 06/22/2005 | EP1543327A2 Method for assaying compounds or agents for ability to decrease the activity of microsomal prostaglandin e synthase or hematopoietic prostaglandin d synthase |
| 06/22/2005 | EP1543169A2 Method for determining sensitivity to a bacteriophage |
| 06/22/2005 | EP1543166A2 Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| 06/22/2005 | EP1543159A2 Antisense modulation of endothelial specific molecule 1 expression |
| 06/22/2005 | EP1543145A2 Antifungal therapeutic targets |
| 06/22/2005 | EP1543110A2 Mesoderm and definitive endoderm cell populations |
| 06/22/2005 | EP1542998A2 Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
| 06/22/2005 | EP1542996A2 Octahydro-2-h-naphtho 1,2-f indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| 06/22/2005 | EP1542729A1 Stable immunogenic product comprising antigenic heterocomplexes |
| 06/22/2005 | EP1542720A2 Treatment of tnf alpha related disorders |
| 06/22/2005 | EP1542708A2 Method for treating inflammatory bowel disease |
| 06/22/2005 | EP1542660A1 Sustained released delivery of amphetamine salts |
| 06/22/2005 | EP1542640A2 Systems and methods for monitoring and enabling use of a medical instrument |
| 06/22/2005 | EP1542609A2 Methods for up-regulating antigen expression in tumors |
| 06/22/2005 | EP1360187B1 3,7-diazabicyclo(3.3.0)octanes and their use in the treatment of cardiac arrhythmias |
| 06/22/2005 | EP1272200B1 Divided dose therapies with vascular damaging activity |
| 06/22/2005 | CN1630635A Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these |
| 06/22/2005 | CN1630531A Composition comprising immunogenic microparticles |
| 06/22/2005 | CN1206998C Composition and method for treating penile erectile dysfunction |
| 06/21/2005 | US6908904 Pharmaceutical preparation and method for treatment of diabetes |
| 06/21/2005 | CA2161970C Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin |
| 06/16/2005 | WO2005053686A1 Indolinone based protein kinase inhibitors |
| 06/16/2005 | WO2005053619A2 Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal |
| 06/16/2005 | WO2005053617A2 Compositions and methods comprising collagen |
| 06/16/2005 | WO2005053616A2 Antimicrobial composition |
| 06/16/2005 | WO2005053614A2 Advanced indolinone based protein kinase inhibitors |
| 06/16/2005 | WO2005053613A2 Combinations for the treatment of fungal infections |
| 06/16/2005 | WO2005053612A2 Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
| 06/16/2005 | WO2005053611A2 Treatment of phosphatidylinositol phospholipid disorders |
| 06/16/2005 | WO2005053610A2 Diamine and iminodiacetic acid hydroxamic acid derivatives |
| 06/16/2005 | WO2005053609A2 Methods of nad+-dependent deacetylase inhibitors |
| 06/16/2005 | WO2005053608A2 Preparing for individualized dosage forms of medicaments |
| 06/16/2005 | WO2005053607A2 Method for preventing hepatic encephalopathic episodes |
| 06/16/2005 | WO2005053605A2 Therapeutic liposomes |
| 06/16/2005 | WO2005053603A2 Antigen receptor variable region typing |
| 06/16/2005 | WO2005053601A2 Methods of generating stem cells and embryonic bodies carrying disease-causing mutations and methods of using same for studying genetic disorders |
| 06/16/2005 | WO2005043123A3 System and apparatus for body fluid analysis using surface-textured optical materials |
| 06/16/2005 | WO2005041877A3 Method of inhibiting rejection following organ transplantation |
| 06/16/2005 | WO2005037200A3 Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| 06/16/2005 | WO2005037188A3 Therapeutic agent for periodontal disease |
| 06/16/2005 | WO2005034883A3 A method of healing skin wounds in mammals and a composition therefor |
| 06/16/2005 | WO2005034864A3 Spine replacement system |
| 06/16/2005 | WO2005032495A8 Gene expression profiles and methods of use |
| 06/16/2005 | WO2005032481A3 Quinazoline derivatives as medicaments |
| 06/16/2005 | WO2005030135A3 Nitrosated glutamic acid compounds, compositions and methods of use |
| 06/16/2005 | WO2005027850A3 Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
| 06/16/2005 | WO2005027832A3 Edta containing compositions and uses thereof |
| 06/16/2005 | WO2005023181A3 Polymeric systems for controlled drug therapy |
| 06/16/2005 | WO2005023180A3 Method for detecting cancer cells and monitoring cancer therapy |
| 06/16/2005 | WO2005023179A3 Combination methods of treating cancer |
| 06/16/2005 | WO2005018571A3 Compositions and methods for treating inflammatory lung disease |
| 06/16/2005 | WO2005018532A3 Purine receptor binding compounds |
| 06/16/2005 | WO2005016255A3 Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds |
| 06/16/2005 | WO2005013920A3 Newcastle disease virus administration |
| 06/16/2005 | WO2005013899A9 Compositions and methods for the therapy and diagnosis of lung cancer |
| 06/16/2005 | WO2005013892A3 Hydrolytically-resistant boron-containing therapeutics and methods of use |
| 06/16/2005 | WO2005011592A3 Substituted indazole-o-glucosides |
| 06/16/2005 | WO2005009388A3 Antiglucocorticoids for the treatment of catatonia |
| 06/16/2005 | WO2005009381A3 Immediate-release formulation of acid-labile pharmaceutical compositions |
| 06/16/2005 | WO2005007117A3 Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| 06/16/2005 | WO2005007098A3 Nucleic acid therapy to enhance cartilage repair |
| 06/16/2005 | WO2005004800A3 Trypanosome derived apoptotic factors (taf) |
| 06/16/2005 | WO2005000235A3 NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME |